J96-31834-33197
2 vaccinations
2 coded responses
23 check-ins
2 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 481 / MI
- Registered
- 2021-01-13
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-13
Registered in v-safe
-
2021-01-13
Dose 1 — Pfizer-BioNTech
- 2021-01-13
- 2021-01-14
- 2021-01-15
- 2021-01-16
- 2021-01-17
- 2021-01-19
- 2021-01-22
- 2021-01-29
-
2021-02-03
Dose 2 — Pfizer-BioNTech
-
2021-02-03
Health check-in — day 0, dose 2Feeling: Fair · Site: Pain · Joint pains, Muscle or body achesAdult check-in
-
2021-02-04
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Pain · Headache, Joint pains, Muscle or body aches, Fatigue or tirednessAdult check-in
- 2021-02-05
-
2021-02-06
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Joint pains, Fatigue or tiredness, Abdominal pain · Be unable to do your normal daily activitiesAdult check-in
- 2021-02-07
-
2021-02-08
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Headache · Be unable to do your normal daily activitiesAdult check-in
- 2021-02-09
- 2021-02-10
- 2021-02-19
- 2021-02-26
- 2021-03-08
- 2021-03-12
- 2021-03-17
-
2021-08-04
Survey response — 6 months, dose 2MedDRA: Condition aggravated, Pre-existing disease, Uterine dilation and curettage, Vaginal haemorrhage — Feeling: Good · Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visit, Emergency room or emergency department visit, HospitalizationFree text: Symptoms: Abnormal vaginal bleeding, flare up of endometriosis and fibriods. · Healthcare visit (other): D&C, Hysteroscopy, laparoscopyMedDRA releases: 2021-09,2024-11 · check-in free text available
-
2021-08-04
Report sent to call center — 6 months, dose 2Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional1 call case(s)
-
2021-10-15
Call successfulDoes not wish to fill out VAERS report
-
2022-02-03
Survey response — 12 months, dose 2MedDRA: COVID-19 — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: CovidMedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-13 | Pfizer-BioNTech | |
| 2 | 2021-02-03 | Pfizer-BioNTech |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2021-08-04 | Successful 2021-10-15 |
Does not wish to fill out VAERS report |
Free text
Release 9 — 6 months, dose 2
Symptoms: Abnormal vaginal bleeding, flare up of endometriosis and fibriods.
Healthcare visit (other): D&C, Hysteroscopy, laparoscopy
Release 11 — 12 months, dose 2
Symptoms: Covid
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Uterine dilation and curettage | ✓ | · | ✓ |
| SD | Condition aggravated | ✓ | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Pre-existing disease | ✓ | · | ✓ |
| SD | Vaginal haemorrhage | ✓ | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release